Humanized anti-HER2 monoclonal antibody; in this trial delivered intrathecally to bind HER2, block receptor signaling, and mediate ADCC within the CSF.
Humanized anti-HER2 (ERBB2) monoclonal antibody that binds HER2 on tumor cells, blocks receptor signaling and downstream proliferative pathways, and induces Fc-mediated ADCC; here administered intrathecally to act within the CSF against leptomeningeal disease.
Trastuzumab binds HER2 on target cells and its Fc engages Fcγ receptor–bearing effector cells (e.g., NK cells, macrophages) to mediate ADCC (and phagocytosis), killing HER2+ cells; it also blocks HER2 signaling.
A B7-H3–targeted antibody-drug conjugate that binds B7-H3 on tumor cells, is internalized, and releases a deruxtecan topoisomerase I inhibitor payload to induce DNA damage and tumor cell death (with potential bystander effect).
Monoclonal antibody targets B7-H3 on tumor cells, undergoes internalization, and releases a deruxtecan topoisomerase I inhibitor payload that induces DNA damage and tumor cell death, with potential bystander killing.
The ADC binds B7-H3 on target cells, is internalized, and releases a deruxtecan topoisomerase I inhibitor that induces DNA damage and apoptosis; the membrane-permeable payload can also cause bystander killing.
Investigational subcutaneous anti-CD38 IgG1 monoclonal antibody expected to mirror daratumumab’s mechanisms (CDC, ADCC, ADCP, apoptosis via Fc cross-linking; depletion of CD38+ immunosuppressive cells).
Anti-CD38 IgG1 monoclonal antibody that binds CD38 on plasma/myeloma and other CD38+ cells, inducing complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP), and triggering apoptosis via Fc cross-linking; also depletes CD38+ immunosuppressive cells to enhance antitumor immunity.
Anti-CD38 IgG1 binds CD38 on target cells and induces complement-dependent cytotoxicity (CDC), NK cell–mediated ADCC, macrophage-mediated ADCP, and apoptosis via Fc cross-linking.
Subcutaneous anti-CD38 human IgG1κ monoclonal antibody (component of DARZALEX FASPRO) mediating CDC, ADCC, ADCP, and apoptosis; depletes CD38+ immunosuppressive cells.
Daratumumab is an anti‑CD38 human IgG1‑kappa monoclonal antibody that binds CD38 on malignant plasma cells and other CD38+ cells, inducing complement‑dependent cytotoxicity, antibody‑dependent cellular cytotoxicity, antibody‑dependent cellular phagocytosis, and apoptosis; it also depletes CD38+ immunosuppressive cells (e.g., Tregs, Bregs, MDSCs), enhancing anti‑tumor immunity.
Anti-CD38 IgG1 binds CD38 on target cells and triggers complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity (NK cells via FcγR), antibody-dependent cellular phagocytosis (macrophages), and can induce apoptosis, killing CD38+ cells.
Humanized IgG1 monoclonal antibody targeting EGFR; blocks ligand binding and receptor activation, inhibiting downstream EGFR-RAS-RAF-MEK-ERK and PI3K-AKT signaling and may elicit ADCC against EGFR-expressing tumor cells.
Humanized IgG1 monoclonal antibody targeting EGFR; binds the extracellular domain to block ligand binding and receptor activation, inhibiting downstream RAS-RAF-MEK-ERK and PI3K-AKT signaling, which suppresses proliferation and survival of EGFR-expressing tumor cells, and may also elicit ADCC.
IgG1 anti-EGFR antibody binds EGFR on tumor cells and recruits immune effectors via Fc–FcγR to mediate ADCC (and possibly CDC), killing EGFR+ cells; EGFR signaling blockade is antiproliferative.